Rapid acting insulin analogues
The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.
1. A fast acting insulin analogue, the insulin analogue consisting of two polypeptide chains, a human A-chain and a human B-chain, the human B chain comprising a substitution, wherein an amino acid residue in position B28 in the human B-chain is substituted with a Glu residue, and wherein the natural His amino acid residue in position 10 in the B-chain is substituted with a Gln and optionally one or more of amino acid residues in position B22-B30 in the human B-chain have been deleted.
2. The fast acting insulin analogue according to claim 1 , wherein an additional amino acid residue in position B22-B30 in the human B-chain is substituted with a Glu or an Asp residue.
3. The fast acting insulin analogue according to claim 1 , wherein an additional amino acid residue in position B25-B30 in the human B-chain is substituted with a Glu or an Asp residue.
4. The fast acting insulin analogue according to claim 2 wherein the amino acid in position B27 is Glu.
5. The fast acting insulin analogue according to claim 1 , wherein the amino acid in position B30 is deleted.
6. The fast acting insulin analogue according to claim 1 , wherein the one or more of amino acid residues in position B22-B30 in the human B-chain have been deleted is selected from the group consisting of amino acid in positions B25, B26 and B27.
7. The fast acting insulin analogue according to claim 6 for the use of treatment of diabetes.
8. A pharmaceutical formulation comprising an insulin analogue according to claim 1 in mixture with a long acting insulin analogue or derivative.
9. A pharmaceutical formulation according to claim 8 , wherein the long acting insulin is an acylated insulin derivative.
10. A pharmaceutical composition according to claim 9 , wherein the long acting acylated insulin is Lys B29 (N ε -tetradecanoyl) des(B30) human insulin (insulin detemir).
11. A pharmaceutical composition according to claim 9 , wherein the long acting insulin is A21Gly, B31Arg, B32Arg human insulin (insulin glargine).